Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-58.33	-56.42	-55.19	872.13	-199.43	-278.02
Depreciation & Amortization	5.97	6.12	6.15	7.02	8.6	6.97
Loss (Gain) From Sale of Assets	0.03	0.03	1.35	-2.72	0.04	-
Asset Writedown & Restructuring Costs	4.51	4.51	-	-	-	-
Loss (Gain) From Sale of Investments	-2.48	-2.51	-1.9	-	-	-
Stock-Based Compensation	21.04	21.39	25.37	39.73	62.06	62.98
Other Operating Activities	-6.39	-5.03	5.56	-960.95	-67.5	-16.9
Change in Accounts Receivable	-0.69	-0.97	-0.69	-2.72	1.8	6.13
Change in Accounts Payable	0.73	0.75	0.01	-1.61	-3.53	3.66
Change in Unearned Revenue	-	-	-0.22	-0.19	-11.46	-26.47
Change in Income Taxes	9.41	9.91	1.1	63.95	-0.19	-8.54
Change in Other Net Operating Assets	58.72	10.67	-8.54	-17.08	-26.17	-12.56
Operating Cash Flow	32.53	-11.54	-27	-186.99	-207.86	-250.4
Capital Expenditures	-0.24	-0.33	-2.49	-0.57	-3.41	-6.62
Sale of Property, Plant & Equipment	-	-	1.51	4.58	0.01	0.06
Investment in Securities	28.42	14.91	-31.72	54.87	127.89	17.27
Other Investing Activities	-2.29	-2.29	-	1,095	-	-
Investing Cash Flow	25.89	12.28	-32.7	1,154	124.49	10.72
Long-Term Debt Issued	-	-	-	-	-	380
Long-Term Debt Repaid	-	-	-	-631.6	-10.73	-235.35
Net Debt Issued (Repaid)	-	-	-	-631.6	-10.73	144.65
Issuance of Common Stock	0.63	0.61	0.62	0.8	111.65	144.98
Repurchase of Common Stock	-2.26	-3.1	-199.55	-132.28	-9.06	-9.75
Other Financing Activities	-	-	-	4.28	-	-16.8
Financing Cash Flow	-1.64	-2.5	-198.93	-758.81	91.86	263.09
Net Cash Flow	56.78	-1.75	-258.63	208.21	8.5	23.4
Free Cash Flow	32.29	-11.87	-29.49	-187.56	-211.26	-257.02
Free Cash Flow Margin	49.47%	-18.43%	-51.35%	-365.29%	-381.96%	-357.68%
Free Cash Flow Per Share	0.66	-0.24	-0.53	-2.55	-3.04	-4.12
Cash Interest Paid	-	-	-	22.24	39.03	24.02
Cash Income Tax Paid	0.12	0.11	0.02	117.97	-4.09	0.01
Levered Free Cash Flow	4.64	-42	-12.22	24	-115.85	-170.49
Unlevered Free Cash Flow	6.24	-40.41	-10.75	27.98	-110.5	-165.15
Change in Net Working Capital	-8.01	41.07	6.25	-31.24	29.23	42.46

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q